Clinical Trials

The aim of this study is to deeply phenotype adult patients and healthy volunteers with varying degrees of sporadic CNS small vessel disease (deep white matter Fazekas scores of 0 to 3). This would be a stage 1 phenotyping exercise of CNS small vessel disease.

The purpose of this study is to better understand specific MRI characteristics of different pediatric disorders affecting the brain using new MRI analysis and imaging techniques to detect and understand subtle changes in specific parts of the brain.

The purpose of this study is to determine if the artificial intelligece (AI)-generated results are less arduous than manual segmentation by radiologists, and determine the non-inferiority of the quality of AI vs. manual segmentation.

The purpose of this study is to evaluate plasma biomarkers of vascular function and inflammation in patients with newly-diagnosed Obstructive Sleep Apnea (OSA) and pre-existing imaging evidence of Cerebral Small Vessel Disease (CSVD).

The purpose of this research is to better understand brain white matter hyperintensities (WMH) in women with migraine. We will accomplish this by comparing brain imaging and clinical assessments of women with migraine, small vessel ischemic (SVI) disease, and multiple sclerosis (MS).

The purpose of this study is to describe cerebral and retinal vasoreactivity in patients with cerebral small vessel disease (SVD) vs. healthy control, to describe temporal change of cerebral and retinal vasoreactivity, and to test the effectiveness of cilostazol in slowing the progression of white matter dementia (WMD).

The aim of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida. The Center will collect and store detailed phenotypic information, DNA, and other biofluids on affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid ...